Abstract
Editor's note:The FDA's decision regarding Intrinsa has potential widespread implications for the medical treatment of female sexual dysfunction (FSD). Dr Andre Guay is a world-renowned authority on the topic of female sexuality and FSD. Accompanying Dr Spark's perspective in issue 2, this perspective will shed important light on the topic and offer insight into the past, present and future of FSD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guay, A. Commentary on androgen deficiency in women and the FDA advisory board's recent decision to request more safety data. Int J Impot Res 17, 375–376 (2005). https://doi.org/10.1038/sj.ijir.3901332
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901332